- Home
- IBRX vs GDS Comparison
IBRX vs GDS Comparison
Compare IBRX & GDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IBRX | GDS |
|---|---|---|
| Founded | 2014 | 2001 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 6.7B |
| IPO Year | 2015 | 2016 |
Fundamental Metrics
Financial Performance| Metric | IBRX | GDS |
|---|---|---|
| Price | $8.24 | $21.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 16 |
| Target Price | $14.25 | ★ $49.28 |
| AVG Volume (30 Days) | ★ 13.5M | 2.5M |
| Earning Date | 11-10-2026 | 11-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $113,288,000.00 | N/A |
| Revenue This Year | $99.98 | $11.60 |
| Revenue Next Year | $108.29 | $9.27 |
| P/E Ratio | ★ N/A | $52.69 |
| Revenue Growth | ★ 668.31 | N/A |
| 52 Week Low | $1.95 | $21.67 |
| 52 Week High | $12.43 | $48.61 |
Technical Indicators
Market Signals| Indicator | IBRX | GDS |
|---|---|---|
| Relative Strength Index (RSI) | 43.83 | 32.26 |
| Support Level | $7.71 | $21.67 |
| Resistance Level | $8.51 | $34.27 |
| Average True Range (ATR) | 0.71 | 1.41 |
| MACD | -0.13 | -0.10 |
| Stochastic Oscillator | 18.18 | 4.60 |
Price Performance
Historical ComparisonAbout IBRX ImmunityBio Inc.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
About GDS GDS Holdings Limited ADS
GDS Holdings started as an IT service provider in 2001, then moved to the data center business with its first self-developed data center opening in 2010. The company now develops and operates data centers in China and also builds, operates, and transfers data centers for other clients. It offers colocation and managed services and mainly targets hyperscale cloud service customers who take large areas of its data centers or even whole data centers under long-term contracts. Its data centers are located predominantly in and around the Tier 1 cities in China, and it has also started expanding into Southeast Asia via the now 23% owned DayOne. GDS listed on the Nasdaq in 2016 and completed a secondary listing in Hong Kong in 2020.